Skip to main content
Log in

PR3-ANCA: a potential biomarker of disease activity for propylthiouracil-induced ANCA-associated vasculitis

  • Correspondence
  • Published:
European Journal of Dermatology

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Dolman KM, Gans RO, Vervaat TJ, et al. Vasculitis and antineutrophil cytoplasmic autoantibodies associated with propylthiouracil therapy. Lancet 1993; 342: 651–2.

    Article  PubMed  CAS  Google Scholar 

  2. Wan P, Zhao X, Hunasehally RY, Shi R, Zheng J. Propylthiouracilinduced ANCA-positive erythema nodosum treated with thalidomide. Int J Dermatol 2012; 51: 345–8.

    Article  PubMed  CAS  Google Scholar 

  3. Wu R, Li R. Propylthiouracil-induced autoimmune syndromes: 11 case reports. Rheumatol Int 2012; 32: 679–81.

    Article  PubMed  Google Scholar 

  4. Gao Y, Chen M, Ye H, Yu F, Guo XH, Zhao MH. Long-term outcomes of patients with propylthiouracil-induced anti-neutrophil cytoplasmic auto-antibody-associated vasculitis. Rheumatology 2008; 47: 1515–20.

    Article  PubMed  CAS  Google Scholar 

  5. Slot MC, Links TP, Stegeman CA, Tervaert JW. Occurrence of antineutrophil cytoplasmic antibodies and associated vasculitis in patients with hyperthyroidism treated with antithyroid drugs: a longterm follow-up study. Arthritis Rheum 2005; 53: 108–13.

    Article  PubMed  Google Scholar 

  6. Balavoine AS, Glinoer D, Dubucquoi S, Wémeau JL. Antineutrophil cytoplasmic antibody-positive small-vessel vasculitis associated with antithyroid drug therapy: How significant is the clinical problem? Thyroid 2015; 25: 1273–81.

    Article  PubMed  CAS  Google Scholar 

  7. Ujihara M, Ishiguro H, Kodama H, Nishiya K, Ikeda M, Kitamura Y. Anti-thyroid drug-induced antineutrophil cytoplasmic antibody (anca)-associated vasculitis. A case report and review of the literature. Jpn J Dermatol 2002; 112: 1229–40.

    Google Scholar 

  8. Yang J, Yao LP, Dong MJ, et al. Clinical characteristics and outcomes of propylthiouracil-induced antineutrophil cytoplasmic antibody-associated vasculitis in patients with Graves’ disease: a median 38-month retrospective cohort study from a single institution in China. Thyroid 2017; 27: 1469–74.

    Article  PubMed  CAS  Google Scholar 

  9. Chen M, Gao Y, Guo XH, Zhao MH. Propylthiouracil-induced antineutrophil cytoplasmic antibody-associated vasculitis. Nat Rev Nephrol 2012; 8: 476–83.

    Article  PubMed  CAS  Google Scholar 

  10. Sera N, Ashizawa K, Ando T, et al. Treatment with propylthiouracil is associated with appearance of antineutrophil cytoplasmic antibodies in some patients with Graves’ disease. Thyroid 2000; 10: 595–9.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Atsushi Fujimoto.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hasegawa, A., Fujimoto, A., Yuki, D. et al. PR3-ANCA: a potential biomarker of disease activity for propylthiouracil-induced ANCA-associated vasculitis. Eur J Dermatol 28, 530–531 (2018). https://doi.org/10.1684/ejd.2018.3314

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1684/ejd.2018.3314

Navigation